ArticleEMBO molecular medicine2020
Early 5-HT
Article in EMBO molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Dually Acting Ligands Targeting Serotonin Receptors: Implications in CNS Disorders.Journal of medicinal chemistry · 2026Review
- 5-HT6 receptors: Contemporary views on their neurobiological and pharmacological relevance in neuropsychiatric disorders.Dialogues in clinical neuroscience · 2025Review
- The antioxidant N-acetylcysteine prevents cortical neuropathological phenotypes caused by adolescent Δ-9-tetrahydrocannabinol exposure in male rats.Translational psychiatry · 2025Article
- Article
- Review
- Superiority of the Triple-Acting 5-HTJournal of medicinal chemistry · 2023Article
- Cognitive Alterations in Addictive Disorders: A Translational Approach.Biomedicines · 2023Review
- Impact of 5-HTCells · 2023Review
- 1-(Arylsulfonyl-isoindol-2-yl)piperazines as 5-HTBiomolecules · 2022Article
- Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment.International journal of molecular sciences · 2022Review
- Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HTJournal of medicinal chemistry · 2021Article
- Blockade of Serotonin 5-HTInternational journal of molecular sciences · 2021Article
- Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement.International journal of molecular sciences · 2021Review
- 2-Phenyl-1ACS chemical neuroscience · 2021Article
- Neuropathology of the Brainstem to Mechanistically Understand and to Treat Alzheimer's Disease.Journal of clinical medicine · 2021Review
- Novel and atypical pathways for serotonin signaling.Faculty reviews · 2021Review
- Down and High: Reflections Regarding Depression and Cannabis.Frontiers in psychiatry · 2021Review
- Early 5-HTEMBO molecular medicine · 2020Article
Corrections and comments
- Erratum issuedEarly 5-HT2022
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
Abstract
Cannabis abuse during adolescence confers an increased risk for developing later in life cognitive deficits reminiscent of those observed in schizophrenia, suggesting common pathological mechanisms that remain poorly characterized. In line with previous findings that revealed a role of 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.